These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10516368)

  • 21. Intravenous or oral iron?
    Littlewood TJ
    Am J Hematol; 2012 Feb; 87(2):134-5. PubMed ID: 22139596
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical management. Where medicine meets management. Pumping iron.
    Peebles G
    Health Serv J; 2004 May; 114(5907):28-9. PubMed ID: 15188729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parenteral iron therapy options.
    Silverstein SB; Rodgers GM
    Am J Hematol; 2004 May; 76(1):74-8. PubMed ID: 15114602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anemia of chronic renal failure: new treatment alternative.
    Seiler S
    CANNT J; 2000; 10(3):35-9, 43-8; quiz 40-2, 49-51. PubMed ID: 11799582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of total dose iron dextran infusion in geriatric patients with chronic kidney disease and iron deficiency anemia.
    Dossabhoy NR; Turley S; Gascoyne R; Tapolyai M; Sulaiman K
    Ren Fail; 2014 Aug; 36(7):1033-7. PubMed ID: 24845687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iron metabolism in end stage renal failure: rationale for re-evaluation of parenteral iron therapy.
    Moe OW; Vazquez M; Kielar M
    Curr Opin Nephrol Hypertens; 2003 Mar; 12(2):145-51. PubMed ID: 12589174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia.
    Auerbach M; Pappadakis JA; Bahrain H; Auerbach SA; Ballard H; Dahl NV
    Am J Hematol; 2011 Oct; 86(10):860-2. PubMed ID: 21922526
    [No Abstract]   [Full Text] [Related]  

  • 28. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI.
    Eschbach JW
    Semin Nephrol; 2000 Jul; 20(4):320-9. PubMed ID: 10928333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute injury with intravenous iron and concerns regarding long-term safety.
    Bishu K; Agarwal R
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Anemia and renal failure: efficacy of its control].
    Fort J
    Nefrologia; 2006; 26 Suppl 3():28-32. PubMed ID: 17469424
    [No Abstract]   [Full Text] [Related]  

  • 31. Intravenous iron therapy in end-stage renal disease.
    Brewster UC
    Semin Dial; 2006; 19(4):285-90. PubMed ID: 16893405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parenteral iron supplementation in patients with end stage renal disease.
    Vogel SC
    ANNA J; 1998 Dec; 25(6):625-30. PubMed ID: 10188399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease].
    Potthoff SA; Münch HG
    Dtsch Med Wochenschr; 2013 Jun; 138(24):1312-7. PubMed ID: 23737117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correction of iron deficiency anaemia using IV CosmoFer in CKD patients with asthma: a prospective study.
    Syed A; Bhandari S
    QJM; 2016 Mar; 109(3):187-90. PubMed ID: 26101227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of iron deficiency by a bolus intravenous iron dextran in peritoneal dialysis].
    Ficheux M; Cuny P; Lecouf A; Ryckelynck JP; Hurault de Ligny B; Lobbedez T
    Nephrol Ther; 2011 Dec; 7(7):558-61. PubMed ID: 21715234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
    Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
    J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to iron sucrose in dialysis patients sensitive to iron dextran.
    Gupta A; Khaira A; Dogra M; Agarwal SK
    Saudi J Kidney Dis Transpl; 2010 Jul; 21(4):744-5; author reply 745. PubMed ID: 20587886
    [No Abstract]   [Full Text] [Related]  

  • 38. Parenteral iron safety and the special article "Just the FAQs: frequently asked questions about iron and anemia in patients with chronic kidney disease".
    Coyne DW
    Am J Kidney Dis; 2002 Jul; 40(1):219-20. PubMed ID: 12087586
    [No Abstract]   [Full Text] [Related]  

  • 39. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
    Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
    Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safe administration of iron dextran to a patient who reacted to the test dose.
    Monaghan MS; Glasco G; St John G; Bradsher RW; Olsen KM
    South Med J; 1994 Oct; 87(10):1010-2. PubMed ID: 7939912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.